RheumaGen, Inc. secured $15 million in Series A financing to advance its innovative gene therapy program RG0401, aimed at providing a one-time curative treatment for treatment-resistant rheumatoid arthritis.

Target Information

RheumaGen, Inc. is an innovative biotechnology company focused on engineering a new class of therapeutics aimed at curing major autoimmune diseases. Based in Aurora, Colorado, RheumaGen is particularly concentrating on editing the human leukocyte antigen (HLA), often referred to as the 'immune gene.' This technology allows for the development of one-time, curative cell and gene therapies aimed at treating severe autoimmune conditions such as rheumatoid arthritis (RA).

The company’s lead program, RG0401, is specifically designed for treatment-resistant or refractory rheumatoid arthritis, a condition that affects 10-20% of RA patients. These individuals often face debilitating symptoms and have significant unmet medical needs. RheumaGen aims to provide a groundbreaking solution with RG0401 by directly addressing the HLA source responsible for the autoimmune response.

Industry Overview

The autoimmune disease treatment market is experiencing significant growth, driven by the increasing prevalence of autoimmune conditions and a rise in demand for effective therapies. In the United States, autoimmune diseases such as